GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VivoSim Labs Inc (NAS:VIVS) » Definitions » Operating Cash Flow per Share

VIVS (VivoSim Labs) Operating Cash Flow per Share : $-8.59 (TTM As of Dec. 2024)


View and export this data going back to 2011. Start your Free Trial

What is VivoSim Labs Operating Cash Flow per Share?

VivoSim Labs's operating cash flow per share for the three months ended in Dec. 2024 was $-1.20. VivoSim Labs's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2024 was $-8.59.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 6.00% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 15.90% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 15.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for VivoSim Labs's Operating Cash Flow per Share or its related term are showing as below:

VIVS' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -445.9   Med: 10.35   Max: 35
Current: 6

During the past 13 years, VivoSim Labs's highest 3-Year average Operating Cash Flow per Share Growth Rate was 35.00% per year. The lowest was -445.90% per year. And the median was 10.35% per year.

VIVS's 3-Year OCF Growth Rate is ranked worse than
53.49% of 1217 companies
in the Biotechnology industry
Industry Median: 9.1 vs VIVS: 6.00

VivoSim Labs Operating Cash Flow per Share Historical Data

The historical data trend for VivoSim Labs's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VivoSim Labs Operating Cash Flow per Share Chart

VivoSim Labs Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Operating Cash Flow per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -27.56 -23.17 -11.66 -17.09 -19.23

VivoSim Labs Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Operating Cash Flow per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.63 -3.20 -2.44 -1.76 -1.20

Competitive Comparison of VivoSim Labs's Operating Cash Flow per Share

For the Biotechnology subindustry, VivoSim Labs's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VivoSim Labs's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VivoSim Labs's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where VivoSim Labs's Price-to-Operating-Cash-Flow falls into.


;
;

VivoSim Labs Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

VivoSim Labs's Operating Cash Flow per Share for the fiscal year that ended in Mar. 2024 is calculated as

Operating Cash Flow per Share (A: Mar. 2024 )=Cash Flow from Operations (A: Mar. 2024 )/Shares Outstanding (Diluted Average) (A: Mar. 2024 )
=-14.653/0.762
=-19.23

VivoSim Labs's Operating Cash Flow per Share for the quarter that ended in Mar. 2024 is calculated as

Operating Cash Flow per Share (Q: Dec. 2024 )=Cash Flow from Operations (Q: Dec. 2024 )/Shares Outstanding (Diluted Average) (Q: Dec. 2024 )
=-1.801/1.505
=-1.20

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


VivoSim Labs Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of VivoSim Labs's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


VivoSim Labs Business Description

Industry
Traded in Other Exchanges
N/A
Address
11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.
Executives
David Gobel director 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Vaidehi Joshi director C/O ORGANOVO HOLDINGS, INC., 11555 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO CA 92121
Alison Tjosvold Milhous director 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Adam K Stern director STERN AEGIS VENTURES, 810 7TH AVENUE 22ND FLOOR, NEW YORK NY 10019
Thomas Hess officer: President, CFO and PFO 366 MADISON AVE. 12TH FLOOR, NEW YORK NY 10017
Douglas Jay Cohen director 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Thomas E Jurgensen officer: General Counsel & Secretary 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Jeffrey N. Miner officer: Chief Scientific Officer 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Chris Heberlig officer: President and CFO C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Keith Murphy director, officer: Executive Chairman 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Steven George Hughes officer: Chief Medical Officer 6275 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Carolyn Beaver director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
David Shapiro director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES ST., NEW YORK NY 10013
Presnell Sharon Collins officer: EVP, Research & Development 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Taylor Crouch director, officer: CEO & President 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075